Back to results
US 2026/0294976 A1Published application
Processes and apparatuses for obtaining amniotic mesenchymal stem cells from amniotic fluid and cells derived thereof
AssigneeAmniotics AB
InventorsJan Talts, Niels-Bjarne Woods, Kåre Engkilde, Marcus Larsson
Life of this patent
Estimating the term…
Abstract
Methods for purifying, culturing and selecting mesenchymal stem cell (MSC) subpopulations with neonatal quality and adult tissue specificity that are for use in production of advanced therapeutic medicinal products.
Claims26
A method for obtaining term amniotic fluid mesenchymal stem cells (TAF MSCs) from term amniotic fluid, comprising:
- providing term amniotic fluid (TAF);
- removing particulate material from the TAF to obtain purified TAF cells;
- performing adherence selection on the purified TAF cells to obtain TAF adherence cells;
- passaging the TAF adherence cells to obtain a population of cells comprising the TAF MSCs;
- and
- selecting the TAF MSCs from the population as cells that express at least one Group A surface marker selected from the group consisting of TBC1 domain family member 3K, allograft inflammatory factor 1 like, cadherin related family member 1, sodium/potassium transporting ATPase interacting 4, ATP binding cassette subfamily B member 1, plasmalemma vesicle associated protein, mesothelin, L1 cell adhesion molecule, hepatitis A virus cellular receptor 1, mal, T cell differentiation protein 2 (gene/pseudogene), SLAM family member 7, double C2 domain beta, endothelial cell adhesion molecule, gamma-aminobutyric acid type A receptor beta1 subunit, cadherin 16, immunoglobulin superfamily member 3, desmocollin 3, regulator of hemoglobinization and erythroid cell expansion, potassium voltage-gated channel interacting protein 1, CD70 molecule, GDNF family receptor alpha 1, crumbs cell polarity complex component 3, claudin 1, novel transcript sodium voltage-gated channel alpha subunit 5, fibroblast growth factor receptor 4, potassium two pore domain channel subfamily K member 3, dysferlin, ephrin A1, potassium inwardly rectifying channel subfamily J member 16, membrane associated ring-CH-type finger 1, synaptotagmin like 1, calsyntenin 2, integrin subunit beta 4, vesicle associated membrane protein 8, G protein-coupled receptor class C group 5 member C, CD24 molecule, cadherin EGF LAG seven-pass G-type receptor 2, cadherin 8, glutamate receptor interacting protein 1, dematin actin binding protein, F11 receptor, cell adhesion molecule 1, cadherin 6, coagulation factor II thrombin receptor like 2, LY6/PLAUR domain containing 1, solute carrier family 6 member 6, desmoglein 2, adhesion G protein-coupled receptor G1, cholecystokinin A receptor, oxytocin receptor, integrin subunit alpha 3, adhesion molecule with Ig like domain 2, cadherin EGF LAG seven-pass G-type receptor 1, and EPH receptor B2, thereby obtaining the TAF MSCs.
3 more elements
A method for obtaining term amniotic fluid lung mesenchymal stem cells (lung TAF MSCs) from term amniotic fluid, comprising:
- providing term amniotic fluid (TAF);
- removing particulate material from the TAF to obtain purified TAF cells;
- performing adherence selection on the purified TAF cells to obtain TAF adherence cells;
- passaging the TAF adherence cells to obtain a population of cells comprising the lung TAF MSCs;
- and
- selecting the TAF lung MSCs from the population as cells that express at least one Group B surface marker selected from the group consisting of PCDH19, DDR1, MME, IFITM10, BGN, NOTCH3, SULF1, TNFSF18, BDKRB1, FLT1, PDGFRA, TNFSF4, UNC5B, FAP, CASP1, CD248, DDR2, PCDH18, LRRC38, and CRLF1, thereby obtaining TAF lung mesenchymal stem cells.
3 more elements
A method for obtaining term amniotic fluid kidney mesenchymal stem (kidney TAF MSCs) cells from term amniotic fluid, comprising:
- providing term amniotic fluid (TAF);
- removing particulate material from the TAF to obtain purified TAF cells;
- performing adherence selection on the purified TAF cells to obtain TAF adherence cells;
- passaging the TAF adherence cells to obtain a population of cells comprising the TAF kidney MSCs;
- and
- selecting the TAF kidney MSCs from the population as cells that express at least one Group C surface marker selected from the group consisting of HAVCR1, CD24, CLDN6, ABCB1, SHISA9, CRB3, AC118754.1, ITGB6, CDH1, LSR, EPCAM, AJAP1, ANO9, CLDN7, EFNA1, MAL2, F11R, L1CAM, GFRA1, IGSF3, TNF, MMP7, FOLR1, TGFA, C3, TNFSF10, PDGFB and WWC1, thereby obtaining TAF kidney MSCs.
3 more elements
A method for obtaining term amniotic fluid skin mesenchymal stem cells (skin TAF MSCs) from term amniotic fluid, comprising:
- providing term amniotic fluid (TAF);
- removing particulate material from the TAF to obtain purified TAF cells;
- performing adherence selection on the purified TAF cells to obtain TAF adherence cells;
- passaging the TAF adherence cells to obtain a population of cells comprising the TAF skin MSCs;
- and
- selecting the skin TAF MSCs from the population as cells that express at least one Group D surface marker selected from the group consisting of TNFSF18, PCDH19, NCAM2, TNFSF4, CD248, DDR2, HTR2B, PCDH18, SULF1, MME, ADGRA2, DCSTAMP, PDGFRA, UNC5B, SCUBE3, CEMIP, BDKRB1, FLT1, BDKRB2, FAP, CASP1, and SRPX2;
- and
- obtaining TAF skin MSCs.
5 more elements
A method for obtaining term amniotic fluid neural mesenchymal stem cells (neural TAF MSCs) from term amniotic fluid, comprising:
- providing term amniotic fluid (TAF);
- removing particulate material from the TAF to obtain purified TAF cells;
- performing adherence selection on the purified TAF cells to obtain TAF adherence cells;
- passaging the TAF adherence cells to obtain a population of cells comprising the TAF neural MSCs;
- and
- selecting the TAF neural MSCs from the population as cells that express at least one Group E surface marker selected from the group consisting of HAVCR1, ACKR3, OSCAR, C3, SIRPB1, SLC6A6, CCKAR, TNFSF10, CLSTN2, TENM2, SFRP1, PIK3IP1, SCNN1D, CLDN11, ALDH3B1, and ITGB4;
- thereby obtaining TAF neural MSCs.
4 more elements
Dependencies are inferred from the claim text.